Gordon, Robert A.
Endeavor Health
4 papers on CoChatORCID 0000-0002-6204-4768
Most cited papers
- Verified
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial
Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 618
- Verified
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 424
- Verified
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial
Kosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Chopra, V., et al. (2021) · The Lancet Diabetes & Endocrinology
COVID-19 Clinical Research StudiesDiabetes Treatment and Management
Cited by 243
- Verified
The black–white factor is g
Gordon, R. A. (1985) · Behavioral and Brain Sciences
Cognitive Abilities and TestingSocial and Intergroup Psychology
Cited by 8
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free